[1] |
HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang.
Comparison of calculation results of five population pharmacokinetic analysis tools
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
|
[2] |
LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua.
Research progress in population pharmacokinetics of rituximab
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
|
[3] |
LIU Wei, XUE Junsheng, YU Zhiheng, WANG Ziyu, CHEN Rong, ZHOU Tianyan.
Interpretation of pharmacokinetic-based criteria for supporting alternative dosing regimens of programmed cell death receptor-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) blocking antibodies for treatment of patients with cancer guidance for industry
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 86-94.
|
[4] |
LIN Liangmo, FU Xiangjun, ZHONG Lili, WANG Hefang, WU Qiongshi, XIAO Jian.
Establishment of population pharmacokinetics model of vancomycin in patients with Neutropenia
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1014-1022.
|
[5] |
ZHANG Ningyuan, ZHENG Xijun, XU Ling, LIU Hongxia, ZHENG Qingshan.
Disease progression model for Alzheimer's disease and its research progress
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 687-694.
|
[6] |
XU Guofang, ZHANG Sisen, LIU Ping, MEI Jiazhuan, LIU Weiwei, LIU Ya'ou, QI Qi.
Population pharmacokinetics of capecitabine in Chinese breast cancer patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 552-559.
|
[7] |
LI Wenchao, BAI Xiangrong, LI Xiaoling, JIANG Dechun.
Population pharmacokinetics/pharmacodynamics of tigecycline in the treatment of different infectious diseases
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1265-1272.
|
[8] |
GUO Xianzhong, LIN Rongfang, LIN Weiwei.
Development of software for individualizing dosage regimens of vancomycin based on population pharmacokinetics models
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(1): 30-39.
|
[9] |
LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang.
Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006.
|
[10] |
LI Jian, YANG Jinbo, WANG Yuzhu.
Discussion on the format and content of new drug population pharmacokinetic study report
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 546-549.
|
[11] |
XU Gaoqi, ZHANG Yiwen, ZHENG Xiaowei, LIU Yujia, LI Li, HUANG Ping.
Missed and remedial dosage regimens of erlotinib by Monte Carlo simulation
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 540-545.
|
[12] |
CHEN Wenjun, RUAN Zourong, XIANG Xiaoqiang.
Development and application progress of physiologically based pharmacokinetic modeling and its combined use with other modeling methods
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 299-305.
|
[13] |
LI Jian, YANG Jinbo, WANG Yuzhu.
Applications of model-informed drug development (MIDD) on new drug research and development
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 1-8.
|
[14] |
LIU Simin, CAI Jun, LI Huixin, YANG Li, ZHAO Yan, ZHANG Jinping.
Research progress in population pharmacokinetics of voriconazole in adults
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1015-1023.
|
[15] |
LI Ling, ZHAO Huijia, CHEN Binyao, LIU Xiaohong, SUN Gongpeng, HAO Zhuowen, FAN Zhipeng, YUE Jiang, WU Jianguo, YE Qifa.
Relevance of CYP2R1 genetic polymorphism and individual therapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1053-1059.
|